Literature DB >> 1499226

Conservative treatment of congenital dislocation of the hip in the newborn and infant.

J A Herring1.   

Abstract

Five practical questions, concerning which hips should be treated, method of treatment, duration of treatment, treatment failure, and whether pretreatment traction is advised in congenitally dislocated hips, are discussed and answered. All hips positive for Ortolani's sign, hips positive for Barlow's sign, dislocated and irreducible hips, and hips that appear unstable by sonography should be treated. A large number of studies document the safety and effectiveness of early treatment in the Pavlik harness. Treatment may be stopped at six weeks in the newborn and three or four weeks after stability is achieved in children three or four months old at the time of initial treatment. Sonography is helpful in determining when to stop treatment. Hips that fail Pavlik harness treatment are at risk to fail with other types of treatment as well and require a cautious approach. Traction before treatment of congenital dislocation of the hip (CDH) may not be necessary. Recent studies have shown that safe reductions may be performed without preliminary traction.

Entities:  

Mesh:

Year:  1992        PMID: 1499226

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  3 in total

1.  Role of ultrasound assessment and harness treatment in the management of developmental dysplasia of the hip.

Authors:  D H Sochart; R W Paton
Journal:  Ann R Coll Surg Engl       Date:  1996-11       Impact factor: 1.891

Review 2.  The treatment of neonatal hip dysplasia with splints in the United Kingdom: time for consensus?

Authors:  Daniel J Westacott; Daniel C Perry
Journal:  J Child Orthop       Date:  2020-04-01       Impact factor: 1.548

3.  Management of developmental dysplasia of the hip in less than 24 months old children.

Authors:  Mehmet Bulut; Murat Gürger; Oktay Belhan; Omer Cihan Batur; Suat Celik; Lokman Karakurt
Journal:  Indian J Orthop       Date:  2013-11       Impact factor: 1.251

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.